标题：替普瑞酮联合兰索拉唑在胃息肉氩离子凝固术后的临床应用

      作者：叶维霞 1，费润欢 2    (1.泸州市人民医院消化内科，四川 泸州 646000；2.陆军军医大学第一附属医院全军消化病研究所，重庆 400038)

      卷次： 2018年29卷13期

      【摘要】 目的 探究替普瑞酮联合兰索拉唑对胃息肉患者氩离子凝固术(APC)后的临床应用效果及安全性。方法 选取2015年4月至2017年4月泸州市人民医院消化内科收治的180例胃息肉患者，按照随机数表法在APC术后将其分为三组，每组60例，对照组采用兰索拉唑单药治疗，Ⅰ组采用替普瑞酮联合兰索拉唑治疗，Ⅱ组采用枸橼酸铋钾联合兰索拉唑治疗，疗程均为4周，比较三组患者在药物治疗2周、4周后胃黏膜愈合情况、临床疗效及不良反应。结果 治疗 2周后，Ⅰ组、Ⅱ组患者的胃黏膜愈合有效率分别为 96.7%、93.3%，均明显高于对照组的83.3%，差异均有统计学意义(P<0.05)；Ⅰ组患者的临床疗效总有效率为98.3%，明显高于对照组的88.3%，差异有统计学意义(P<0.05)，Ⅱ组患者临床疗效总有效率为 96.7%，高于对照组，但差异无统计学意义(P>0.05)；治疗 4周后，三组患者的胃黏膜愈合有效率和临床疗效相当，差异均无统计学意义(P>0.05)。在整个疗程中，Ⅰ组患者的不良反应发生率为 1.7%，明显低于Ⅱ组的 11.7%，差异有统计学意义(P<0.05)，而Ⅰ组与对照组比较，差异无统计学意义(P>0.05)。结论 替普瑞酮联合兰索拉唑能有效促进胃息肉患者APC术后胃黏膜愈合，不良反应少，安全性好，在临床上具有实际应用价值。
      【关键词】替普瑞酮；兰索拉唑；氩离子凝固术；胃息肉；疗效
      【中图分类号】 R656.6+1 【文献标识码】 A 【文章编号】 1003—6350（2018）13—1887—04

Clinical application of teprenone combined with lansoprazole in patients with gastric polyps after argon plasmacoagulation.
YE Wei-xia 1, FEI Run-huan 2. 1. Department of Gastroenterology, Luzhou People’s Hospital, Luzhou 646000, Sichuan,CHINA; 2. Institute of Gastroenterology, the First Affiliated Hospital of Army Medical University, Chongqing 400038, CHINA
【Abstract】 Objective To explore the clinical efficacy and safety of the combination therapy of teprenone andlansoprazole in patients with gastric polyps after argon plasma coagulation (APC). Methods A total of 180 patientswith gastric polyps, who admitted to Department of Gastroenterology of Luzhou People’s Hospital from April 2015 toApril 2017, were selected and divided into three groups after post-APC by random number table method, with 60 casesin each group. The control group was treated with lansoprazole monotherapy, groupⅠ was treated with teprenone com-bined with lansoprazole, and group Ⅱ was treated with bismuth potassium citrate combined with lansoprazole. Thecourse of treatment was 4 weeks. The healing of gastric mucosa, clinical efficacy and adverse reactions among the threegroups were compared after 2 weeks and 4 weeks of treatment. Results After 2 weeks of treatment, the healing rate ofgastric mucosain in the group Ⅰ and Ⅱ were respectively 96.7% and 93.3% , which were significantly higher than83.3% in the control group (P<0.05). The clinical efficacy in group Ⅰ was 98.3%, which was significantly higher than88.3% in the control group (P<0.05), and the clinical efficacy in the groupⅡ (96.7%) was slightly higher than that in thecontrol group (P>0.05). After 4 weeks of treatment, the healing of gastric mucosa and clinical efficacy among threegroups had no statistical differences (P>0.05). During the course of treatment, the incidence of adverse reactions in thegroupⅠ was 1.7%, which was significantly lower than 11.7% in the groupⅡ (P<0.05), while the groupⅠ and the con-trol group showed no significant difference (P>0.05). Conclusion The combination therapy of teprenone and lansopra-zole could effectively promote the healing of gastric mucosa after APC in patients with gastric polyp, with the advantag-es of little adverse reactions, good safety. It is worth promoting in clinical practice.
      【Key words】 Teprenone; Lansoprazole; Argon plasma coagulation; Gastric polyp; Curative effect·临床经验·doi:10.3969/j.issn.1003-6350.2018.13.034基金项目：四川省泸州市科技计划项目[编号：2013-S-46(6/6)]